Overview
- The facility will be built at Leiden Bio Science Park in Katwijk, with construction expected to begin in 2026 and staffing projected at about 500 manufacturing roles plus roughly 1,500 construction jobs.
- The site will produce orforglipron, Lilly’s oral small‑molecule GLP‑1 candidate for weight loss, alongside oral medicines in cardiometabolic disease, neuroscience, oncology and immunology.
- Lilly outlined advanced features for the plant, including automated material handling, paperless systems, spray‑dried dispersion technology and process analytical technology.
- The Netherlands investment follows a $1.2 billion expansion in Carolina, Puerto Rico, and is part of a broader U.S. manufacturing push totaling $50 billion with two additional U.S. sites expected to be announced.
- Lilly plans global regulatory submissions for orforglipron by the end of 2025 and has said the drug met most criteria for the FDA’s national priority voucher, which could cut review times to one to two months; the Dutch project remains subject to regulatory and local approvals.